All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 197 of 206 pages ‹ First < 195 196 197 198 199 > Last ›
HSL16711
Bargmann E, Wolfe S
Letter to the Editor concerning Long Term Diazepam Therapy
JAMA 1984;251:1555
HSL3173
Ball JG, Snell ES.
Payments to doctors and the responsibilities of ethics committees
British Medical Journal 1983 Dec 17;287:1884
HSL8446
Government says no to substitution-and cuts industry's profits
Pharmaceutical Journal 1983 Dec 17;231:726-727
HSL19895
Round the World: Malaysia: Call For Reform of Drug Policies
The Lancet 1983 Dec 17;1412
HSL8447
White JP.
Prescriptions: new products set pace
Drug Topics 1983 Dec 12;127:53-54, 56
HSL3171
Howie JG.
Doctors and the pharmaceutical industry [1st of 2 letters]
Journal of the Royal College of General Practitioners 1983 Dec;33:825
HSL3172
Taylor GB.
Doctors and the pharmaceutical industry [2nd of 2 letters]
Journal of the Royal College of General Practitioners 1983 Dec;33:825
HSL8406
Brodrick A, Preece G, Bird HA, Wright V.
Factors that may influence the prescribing habits of rheumatologists.
J Clin Hosp Pharm 1983 Dec;8:(4):333-8
HSL8438
Rosen AM.
Bringing reason to the drug advertising debate
Pharmaceutical Technology 1983 Dec;7:20-21
HSL16709
Wolfe S
Don't Ignore This Danger Signal
USA Today 1983 Nov 23
HSL3169
Re: the promotion of products containing amidopyrine
1983 Nov;
HSL3170
Tiranti D.
Hunger and the wonder drug
New Internationalist 1983 Nov
HSL8440
Rosen AM.
In favor of consumer Rx ads: let's argue examples, not principles
Pharmaceutical-Executive 1983 Nov;3:26, 92
HSL16708
Wolfe S
Non?Prescription Drugs: How Safe?
The LA Times 1983 Oct 24
HSL5229
Rovner S.
Health Talk: Mixed Bag
The Washington Post 1983 Oct 21
HSL3135
Avorn J, Soumerai SB.
A new approach to reducing suboptimal drug use.
JAMA 1983 Oct 7;250:(13):1752-3
HSL3136
Barker C.
The Mozambique pharmaceutical policy.
Lancet 1983 Oct 1;2:(8353):780-2
HSL3168
Phillips DJ, Smith JE.
Hospital-based training for pharmaceutical manufacturers' representatives.
Am J Hosp Pharm 1983 Oct;40:(10):1661-3
HSL8407
Miller RW.
Would Rx ads make people learn or yearn?
FDA Consum 1983 Oct;17:(8):24-7
HSL8448
Cardinale V, Glaser M.
Selling of the pharmacy
Drug Topics 1983 Sep 5;127:38-42, 44, 49
HSL8402
Van der Geest S
Medicines in the third world; sale without restriction and misuse
Pharmaceutisch Weekblad 1983 Sep 2;1118:723-732
HSL3166
Millstein LG.
The regulation of prescription drug advertising.
Am Pharm 1983 Sep;NS23:(9):54-7
HSL3167
Schofield TP.
The relationship between the college and the pharmaceutical industry.
J R Coll Gen Pract 1983 Sep;33:(254):601-3
HSL8442
These low pressure ladies form a potent sales force
American Druggist 1983 Sep;188:140, 142
HSL8443
Lamy PP.
Drug abuse by older adults--who is responsible?
Drug Intell Clin Pharm 1983 Sep;17:(9):657-9
HSL8453
Nonprescription drug sales up in 82
American Pharmacy 1983 Sep;13
HSL8455
Curtiss FR.
Pharmacy management strategies for responding to hospital reimbursement changes
American Journal of Hospital Pharmacy 1983 Sep;40:1489-1492
HSL8436
Schwartz H.
Rx TV ads: fad or fixture?
Pharmaceutical Executive 1983 Aug;3:12, 14
HSL8437
Kaplan A, Becker R.
Constitutional issues in the Boots aftershock
Pharmaceutical Executive 1983 Aug;3:78, 80
HSL8452
Final judgment on advertising - US District Court
American Pharmacy 1983 Aug;54-56
HSL3133
Pharmaceutical policies for the Third World--whose responsibility.
Lancet 1983 Jul 16;2:(8342):144
HSL3152
Musher DM.
Antibiotics: the medium is the message.
Rev Infect Dis 1983 Jul-Aug;5:(4):809-12
HSL3165
Willcox GS, Mahoney CD, Jeffrey LP.
Monitoring the hospital activities of medical service representatives.
Am J Hosp Pharm 1983 Jun;40:(6):989-91
HSL3131
Drug companies and rheumatologists.
Br J Rheumatol. 1983 May 22;2:65-6
HSL8450
Mercill AW.
Searching for O-T-C opportunities
Pharmaceutical Executive 1983 May;3:26-29
HSL8451
Kushner D.
Make pharmacists your partners in O-T-C promotion
Pharmaceutical Executive 1983 May;3:30-31
HSL3164
Kolata G.
Prescription drug ads put FDA on the spot.
Science 1983 Apr 22;220:(4595):387-8
HSL8449
Millstein LG.
FDA policy on comparative prescription drug advertising
Drug Information Journal 1983 Apr 7;17:63-66
HSL3139
Brooks PM, Birkett D.
Release of new drugs. The lessons of benoxaprofen
Med J Aust. 1983 Mar 19;1:(6):251-2
HSL8403
Plumridge RJ.
Review of factors influencing drug prescribing. Part 1
Australian Journal of Hospital Pharmacy 1983 Mar;13:16-19
HSL3162
Getting good value from drug reps.
Drug Ther Bull. 1983 Feb 25;21:(4):13-5
HSL3130
Doctors and the drug industry.
Br Med J (Clin Res Ed). 1983 Feb 19;286:(6365):579-80
HSL8456
van der Geest S
Non-information for patients: selling drugs in developing countries
Pharm Int 1983 Feb;4:42-44
HSL8462
Some Rx drug makers are using discount coupons
American Druggist 1983 Feb;187: 53
HSL3132
'Opren scandal'
Lancet 1983 Jan 29;1(8318):219-20 1983 Jan 29;1:(8318):219-20
HSL3161
Mangold T.
Relationships between doctors and salesment are lurching out of control
The Listener (London) 1983 Jan 202-4
HSL3147
Harvey K.
Promotion of newer antimicrobial agents.
Med J Aust 1983 Jan 8;1:(1):27-8
HSL3154
Osifo NG.
Overpromotion of drugs in international product package inserts.
Trop Doct 1983 Jan;13:(1):5-8
HSL3160
Massengill R Jr, Verghese A, Robert T.
Course for drug representatives.
J Med Educ 1983 Jan;58:(1):86
HSL3134
Alloza JL, Lasagna L.
A comparison of drug product information in four national compendia
Clinical Pharmacology and Therapeutics 1983;33:269-277
HSL3137
Beardshaw V.
Prescription for change: Health Action International’s guide to rational health projects
1983;
HSL3138
Breslow RA.
Junk mail
New England Journal of Medicine 1983;308:1168
HSL3140
Connors JM.
More on junk mail
New England Journal of Medicine 1983;309:673-674
HSL3141
De Maar EW, Kshirsagar NA, Darmansjah I.
An Asian perspective on drug and related health care information.
Drug Inf J 1983;17:(4):263-9
HSL3142
Deitch R.
The government and the activities of the pharmaceutical industry
Lancet 1983;2:1432-1433
HSL3143
French TA.
Commercial approach of pharmaceutical industry
BMJ 1983;287:1632
HSL3144
Generali JA, Hogan L.
A comparison of pharmaceutical manufacturers as a source of drug information to a telephone inquiry: generic vs brand.
Drug Inf J 1983;17:(3):195-204
HSL3145
Goldberg D.
Tales from the Vienna Woods
Lancet 1983;2:393
HSL3146
Gray R, Smith M.
Is criticism of tranquilizer advertising justified?
Medical Marketing & Media 1983;18:(7):50, 52, 54-55, 58-59
HSL3148
Kass EH.
Seduction in a grand hotel
Reviews of Infectious Diseases 1983;5:973-974
HSL3149
Klein T.
Detailing and other forms of promotion
1983;400-417
HSL3150
Lumbard J.
Foremost problem? Medical service representatives
Hospital Pharmacy 1983;18:134
HSL3151
McAuley RG, Little F.
Junk mail
Canadian Medical Association Journal 1983;129:1174, 1176
HSL3153
O’Connor JF.
Research, critical thinking and the pharmaceutical industry
Nova Scotia Medical Bulletin 1983;62:66
HSL3155
Phillips I.
Supplements
Journal of Antimicrobial Chemotherapy 1983;12:199-200
HSL3156
Quraeshi ZA, Luqmani M, Malhotra N.
Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
J Health Care Mark 1983 Fal;3:(4):27-37
HSL3157
Smith MC.
An analysis of the impact of print advertising on prescribing
1983;259-278
HSL3158
Waldman RH.
Cost of antibiotics
JAMA 1983;250:1693-1694
HSL3159
Wright L.
Pharmaceutical advertising
New Zealand Medical Journal 1983;96:407
HSL3163
Truth in drug advertising
Dispatch 1983;(25):1-5
HSL3174
Gundry DRT.
The big spenders
British Medical Journal 1983;287:1884
HSL8435
Wahli HR.
Information for the patient-information for the doctor
Swiss Pharma 1983;5:(11):7-14
HSL8439
Koskikallio I.
Special characteristics of drugs and drug markets
Journal of Drug Issues 1983;13:(1):167-177
HSL8445
Marcus D.
FDA approval of comparative claims for prescription drugs--the Moxam case.
Drug Inf J 1983;17:(3):171-5
HSL16707
Wolfe S
Review of Prescriptions for Death: The Drugging of the Third World
Journal of Public Health Policy 1983;4:(1):115‑116
HSL16712
Bargmann E, Greenberg A, Kowey P, Wolfe S
Letter to the Editor on Conflicting Views Regarding the Frequency of Unnecessary Pacemaker Implants
Am. J. Cardiol 1983;51:1042‑1043
HSL3097
The influence of drug advertisements.
Lancet. 1982 Dec 4;2:(8310):1257-8
HSL8459
Laitin JA, Getyer EG.
Borrowing a European success: prescription pad advertising
Pharmaceutical Executive 1982 Dec;2:38-39
HSL3115
O'Malley K, O'Hanrahan M.
Drug promotion and the doctor.
Br J Clin Pharmacol 1982 Nov;14:(5):661-4
HSL3120
Snell ES.
Drug promotion and the doctor--a reply.
Br J Clin Pharmacol 1982 Nov;14:(5):664-6
HSL3117
Rochmis PG.
Seminars for physicians.
JAMA 1982 Oct 1;248:(13):1580-1
HSL3129
Kushner D.
Two-thirds of RPh's & MD's object to makers' promotion of Rx drugs to the public
American Druggist 1982 Oct;186:(1):14, 16, 21-22
HSL8457
Buc NL.
Current regulatory issues in marketing prescription drugs: comparative claims and advertising to consumers
Food Drug Cosmet Law J 1982 Oct;37:402-408
HSL8458
Two-thirds of RPh's and MD's object to makers' promotion of Rx drugs to the public
American Druggist 1982 Oct;186:14, 16, 21-22
HSL8460
Lubman S.
Is patent extension necessary?
Pharmaceutical Technology 1982 Oct;6:26-27
HSL8463
Oliver C.
Made in New York: good prescription for the pharmaceutical industry
Pharmaceutical Executive 1982 Oct;2:56, 60
HSL8466
Chain pharmacists are found more likely than indeps to use unbranded generics
American Druggist 1982 Oct;186:13, 70, 72, 76, 79, 82, 86, 88
HSL19896
Lasagna L
Book Review: Prescriptions for Death: The Drugging of the Third World
NEJM 1982 Sep 23;830
HSL16706
Wolfe S
Oraflex: Who Learned?
The Washington Post 1982 Sep 20
HSL8469
Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration.
Fed Regist 1982 Sep 7;47:(173):39249-50
HSL3099
Bainbridge CV, D'Ambrosio GG, Petrick RJ, Weiss EM.
Pharmaceutical manufacturer's responses to drug information inquiries.
Am J Hosp Pharm 1982 Sep;39:(9):1532-4
HSL16703
Wolfe, S
Benoxaprofen
BMJ 1982 Sep;285:(6344):809
HSL3128
Budiansky S.
Drug promotion: FDA steps in
Nature 1982 Aug 26;298:784-785
HSL8461
Hager T.
Therapeutic substitution: drawing the battle lines
Pharmaceutical Executive 1982 Aug;2:59-62
HSL20039
King K
Doctors and drug companies
MJA 1982 July 24;63
HSL2065
Avorn J, Chen M, Hartley R.
Scientific versus commercial sources of influence on the prescribing behavior of physicians.
Am J Med 1982 Jul;73:(1):4-8
HSL3107
Hatton RC, Doering PL, Frias JL.
Physicians' sources of information about teratogenic effects of drugs.
Drug Inf J 1982 Jul-Sep;16:(3):148-53
HSL3127
McGhan W, Seery S, Hill B, Koda R.
Hospital pharmacists' attitudes towards medical services representatives: a comparison of directors, staff, and clinical pharmacists.
Hosp Formul 1982 Jul;17:(7):957-61
HSL8468
Medicines Act 1968: procedure drawn up for pursuing changes in legal status of medicines
Pharmaceutical Journal 1982 Jul;229:54-55
HSL8467
Prescription of generics and the pharmaceutical industry
Cienc Ind Farm 1982 Jun;1:217
Page 197 of 206 pages ‹ First < 195 196 197 198 199 > Last ›
